Send In The Senolytics
Elie Dolgin’s recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.